News & Updates

Two new compounds that are set to introduce advancements in the treatment landscape for Alzheimer's disease were approved by the US FDA within 1 month

Nearly half of dementia cases could be prevented or delayed by addressing 14 modifiable risk factors starting from childhood, including two new risk factors – high LDL-cholesterol (LDL-C) level and untreated vision loss – according to a report of the 2024 Lancet Commission on dementia.

Individuals with obesity who underwent a short-term, low-calorie diet demonstrate a multifaceted body response, including an increased brain connectivity in the limbic‒temporal network (emotion and memory) as well as hormone and eating behaviour changes that seem relevant for recovering the weight lost, a recent study has shown.

Prothrombin complex concentrate (PCC) treatment does not improve functional outcomes or reduce haematoma expansion or mortality in Chinese atrial fibrillation (AF) patients with direct-acting oral anticoagulant (DOAC)–associated intracerebral haemorrhage (ICH), researchers from the Chinese University of Hong Kong (CUHK) have reported.

Circadian rhythm disruption appears to precede the accumulation of amyloid-beta plaques and potentially represents a modifiable risk factor for Alzheimer's disease (AD), according to a study.

A study presented at EAN 2024 found that selective exposure to parental smoking at an early age may increase the risk of developing multiple sclerosis (MS) later in life.

Conditional orders of low molecular weight heparin (LMWH) based on platelet values appears safe and effective in the treatment of venous thromboembolism (VTE) in patients with malignant haematology (MH) experiencing thrombocytopenia, a study has shown. In addition, worsening or new VTE has not been reported among study participants.